Carlsberg A/S: Solid Start to 2026, Deleveraging Path Supports Overweight

Core Conclusion

Carlsberg is maintained Overweight with a target price of DKr 1,035 (from DKr 1,015), representing 23.8% upside from the closing price of DKr 836. The thesis rests on three pillars: a solid Q1 2026 execution that de-risks the full-year outlook, a clear deleveraging trajectory post-Britvic that enables resumption of buybacks, and an attractive valuation below both historical averages and European staples peers. The modest target price increase reflects a roll-forward of DCF; key estimates remain broadly unchanged.

What the Market May Be Underappreciating

The most under-appreciated factor is the speed of balance sheet repair. Net debt/EBITDA is projected to fall to 2.5x by 2027, unlocking capital return optionality. While the Iran situation introduces headline uncertainty, management’s explicit confidence in securing additional Pepsi licenses (not yet in estimates) offers an asymmetric upside that the current risk-reward does not price. Additionally, Q1 volumes and revenues benefitted from phasing (Easter, Lunar New Year) but still reflect an organic beer volume improvement from -2.9% (FY25) to +1.2% (FY26e), a structural turn that supports HSD% EPS compounding.

Evidence Chain

• Q1 2026 performance: Organic beer volume growth of 1.2% vs -2.9% in FY25; organic net revenue growth of 4.0%; organic operating profit growth of 5.2%. This is within or above the guided range for FY26.
• Britvic synergies: The acquisition increase leverage temporarily, but strong cash flow plus announced synergy realization will bring net debt/EBITDA to 2.5x by 2027, enabling share buybacks.
• Pepsi license optionality: Management expressed confidence in securing more licenses. The Kazakhstan Pepsi addition is already reflected in FY27 organic growth acceleration to +9.9% in the bull case, but base estimates exclude further wins.
• EPS growth trajectory: 8% EPS CAGR (FY25-28e) to DKr 77.68 (FY28e), placing Carlsberg in the top quartile of European consumer staples growth.
• Valuation support: Target price derived from average of DCF (DKr 1,000; WACC 8.1%, TG 2.5%) and P/E (DKr 1,070; ~16x CY26e P/E, in line with 10-year average relative to EU staples). Current price implies ~12.5x CY26e P/E, a ~2-turn discount to the 10-year average relative multiple.

Key Risks

• Geopolitical: Escalation of the Iran situation could weigh on sentiment and regional operations, though direct financial exposure is limited.
• Input costs / margin: Significant inflation in raw materials or adverse FX could pressure organic EBIT growth below the 5.2% base case.
• China recovery: Mainland China contributes 10-20% of revenue; a slower-than-expected mid-term recovery would pressure the top line.
• Competition: Increased intensity in key regions (e.g., China, UK) could compress margins.
• Pepsi license dependency: If further licenses are not secured, the bull-case upside (DKr 1,305) recedes, but base case does not assume them.

Valuation & Trade Implication

At DKr 836, the stock trades at 12.5x CY26e PE – a 20% discount to European staples – for an 8% EPS CAGR. The options-implied probability distribution shows a 15.6% probability of reaching the base case (DKr 1,035) and an asymmetric skew to the downside (31.7% probability of bear case DKr 775). This skew partially reflects the Iran overhang but does not account for the potential catalysts (deleveraging, buybacks, Pepsi licenses). For investors with a 12-18 month horizon, the risk-reward remains favorable: the base case upside of 23.8% outweighs the bear case downside of 7.3% on a probability-weighted basis. We recommend maintaining Overweight positioning, with the expectation that deleveraging and organic growth momentum will narrow the discount.